Logo

InterVenn Biosciences: John Leite

Dec 03, 2020

John Leite has become chief business officer at InterVenn Biosciences, based in South San Francisco. Previously, he was VP of oncology, market development, and product marketing for Illumina's oncology business. Prior to that, he was VP of commercial strategy and market access for Genoptix, and earlier in his career, he was a scientist at Invitrogen. Leite holds a PhD in biochemistry from the University of Pittburgh School of Medicine.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.